Utility of adjuvant systemic therapy in melanoma

A. M M Eggermont, A. Testori, J. Marsden, P. Hersey, I. Quirt, T. Petrella, H. Gogas, R. M. MacKie, A. Hauschild

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease. To date, chemotherapy, immunostimulants and vaccines have been used with minimal success. Interferon (IFN) has shown an effect on relapse-free survival (RFS) in several clinical trials; however, without a clinically significant effect on overall survival (OS). A recently conducted meta-analysis demonstrated prolongation of disease-free survival (DFS) in 7% and OS benefit in 3% of IFN-treated patients when compared with observation-only patients. There were no clear differences for the dose and duration of treatment observed. Observation is still an appropriate control arm in adjuvant clinical trials. Regional differences exist in Europe in the adjuvant use of IFN. In Northwest Europe, IFN is infrequently prescribed. In Central and Mediterranean Europe, dermatologists commonly prescribe low-dose IFN therapy for AJCC stage II and III disease. High-dose IFN regimens are not commonly used. The population of patients that may benefit from IFN needs to be further characterised, potentially by finding biomarkers that can predict response. Such studies are ongoing.

Original languageEnglish
JournalAnnals of Oncology
Volume20
Issue numberSUPPL. 4
DOIs
Publication statusPublished - 2009

Fingerprint

Interferons
Melanoma
Therapeutics
Survival
Observation
Clinical Trials
Immunologic Adjuvants
Disease-Free Survival
Meta-Analysis
Vaccines
Biomarkers
Recurrence
Drug Therapy
Pharmaceutical Preparations
Population

Keywords

  • Adjuvant therapy
  • Interferon
  • Melanoma
  • Metastasis
  • Randomised trials

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Eggermont, A. M. M., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., ... Hauschild, A. (2009). Utility of adjuvant systemic therapy in melanoma. Annals of Oncology, 20(SUPPL. 4). https://doi.org/10.1093/annonc/mdp250

Utility of adjuvant systemic therapy in melanoma. / Eggermont, A. M M; Testori, A.; Marsden, J.; Hersey, P.; Quirt, I.; Petrella, T.; Gogas, H.; MacKie, R. M.; Hauschild, A.

In: Annals of Oncology, Vol. 20, No. SUPPL. 4, 2009.

Research output: Contribution to journalArticle

Eggermont, AMM, Testori, A, Marsden, J, Hersey, P, Quirt, I, Petrella, T, Gogas, H, MacKie, RM & Hauschild, A 2009, 'Utility of adjuvant systemic therapy in melanoma', Annals of Oncology, vol. 20, no. SUPPL. 4. https://doi.org/10.1093/annonc/mdp250
Eggermont AMM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T et al. Utility of adjuvant systemic therapy in melanoma. Annals of Oncology. 2009;20(SUPPL. 4). https://doi.org/10.1093/annonc/mdp250
Eggermont, A. M M ; Testori, A. ; Marsden, J. ; Hersey, P. ; Quirt, I. ; Petrella, T. ; Gogas, H. ; MacKie, R. M. ; Hauschild, A. / Utility of adjuvant systemic therapy in melanoma. In: Annals of Oncology. 2009 ; Vol. 20, No. SUPPL. 4.
@article{99ed148c58e744598cc4c13f082c1075,
title = "Utility of adjuvant systemic therapy in melanoma",
abstract = "The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease. To date, chemotherapy, immunostimulants and vaccines have been used with minimal success. Interferon (IFN) has shown an effect on relapse-free survival (RFS) in several clinical trials; however, without a clinically significant effect on overall survival (OS). A recently conducted meta-analysis demonstrated prolongation of disease-free survival (DFS) in 7{\%} and OS benefit in 3{\%} of IFN-treated patients when compared with observation-only patients. There were no clear differences for the dose and duration of treatment observed. Observation is still an appropriate control arm in adjuvant clinical trials. Regional differences exist in Europe in the adjuvant use of IFN. In Northwest Europe, IFN is infrequently prescribed. In Central and Mediterranean Europe, dermatologists commonly prescribe low-dose IFN therapy for AJCC stage II and III disease. High-dose IFN regimens are not commonly used. The population of patients that may benefit from IFN needs to be further characterised, potentially by finding biomarkers that can predict response. Such studies are ongoing.",
keywords = "Adjuvant therapy, Interferon, Melanoma, Metastasis, Randomised trials",
author = "Eggermont, {A. M M} and A. Testori and J. Marsden and P. Hersey and I. Quirt and T. Petrella and H. Gogas and MacKie, {R. M.} and A. Hauschild",
year = "2009",
doi = "10.1093/annonc/mdp250",
language = "English",
volume = "20",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Utility of adjuvant systemic therapy in melanoma

AU - Eggermont, A. M M

AU - Testori, A.

AU - Marsden, J.

AU - Hersey, P.

AU - Quirt, I.

AU - Petrella, T.

AU - Gogas, H.

AU - MacKie, R. M.

AU - Hauschild, A.

PY - 2009

Y1 - 2009

N2 - The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease. To date, chemotherapy, immunostimulants and vaccines have been used with minimal success. Interferon (IFN) has shown an effect on relapse-free survival (RFS) in several clinical trials; however, without a clinically significant effect on overall survival (OS). A recently conducted meta-analysis demonstrated prolongation of disease-free survival (DFS) in 7% and OS benefit in 3% of IFN-treated patients when compared with observation-only patients. There were no clear differences for the dose and duration of treatment observed. Observation is still an appropriate control arm in adjuvant clinical trials. Regional differences exist in Europe in the adjuvant use of IFN. In Northwest Europe, IFN is infrequently prescribed. In Central and Mediterranean Europe, dermatologists commonly prescribe low-dose IFN therapy for AJCC stage II and III disease. High-dose IFN regimens are not commonly used. The population of patients that may benefit from IFN needs to be further characterised, potentially by finding biomarkers that can predict response. Such studies are ongoing.

AB - The lack of effective drugs in stage IV melanoma has impacted the effectiveness of adjuvant therapies in stage II/III disease. To date, chemotherapy, immunostimulants and vaccines have been used with minimal success. Interferon (IFN) has shown an effect on relapse-free survival (RFS) in several clinical trials; however, without a clinically significant effect on overall survival (OS). A recently conducted meta-analysis demonstrated prolongation of disease-free survival (DFS) in 7% and OS benefit in 3% of IFN-treated patients when compared with observation-only patients. There were no clear differences for the dose and duration of treatment observed. Observation is still an appropriate control arm in adjuvant clinical trials. Regional differences exist in Europe in the adjuvant use of IFN. In Northwest Europe, IFN is infrequently prescribed. In Central and Mediterranean Europe, dermatologists commonly prescribe low-dose IFN therapy for AJCC stage II and III disease. High-dose IFN regimens are not commonly used. The population of patients that may benefit from IFN needs to be further characterised, potentially by finding biomarkers that can predict response. Such studies are ongoing.

KW - Adjuvant therapy

KW - Interferon

KW - Melanoma

KW - Metastasis

KW - Randomised trials

UR - http://www.scopus.com/inward/record.url?scp=70349577393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349577393&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp250

DO - 10.1093/annonc/mdp250

M3 - Article

VL - 20

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 4

ER -